The Ontario Genomics Institute announced today that it has awarded MaRS client InDanio BioScience $100,000 of development funding under its Pre-Commercialization Business Development Fund (see press release here).

InDanio Bioscience has developed a revolutionary approach to drug discovery based on human nuclear receptor gene expression.  Using the InDanio approach, drug developers can quickly confirm which nuclear receptor is targeted and also the main tissues where the drug is active.

Nuclear receptors are common drug targets and having greater insight into the impact of novel drugs on these receptors is of great commercial value.

John McCulloch

John provides assistance to life sciences entrepreneurs in business strategy, management, intellectual property, financing and licensing. See more…